Research

Hormonal

GLP-1 agonists do not directly cause acne vulgaris; reported acne-like symptoms are likely injection-site hypersensitivity reactions or secondary to weight-loss-induced hormonal changes (e.g., IGF-1 increases).

If you are using a GLP-1 agonist and develop acne, it is likely not the drug directly attacking your skin. Instead, the weight loss you are experiencing may trigger hormonal shifts (like increased IGF-1) that worsen acne. Alternatively, any lumps you see are likely injection-site reactions, not acne. Consult your doctor to distinguish between these causes.

ModerateRefutesMEDIUM confidence
It is unlikely that GLP-1 agonists themselves are directly responsible for the acne that some patients may develop during treatment. Rather, it is more probable that the weight loss yielded by treatment with these drugs may induce intrinsic physiologic and hormonal changes that induce or exacerbate acne vulgaris in such patients.
Oluwafunke Oluwatosin Ogunremi et al. · International Journal of Women’s Dermatology · 2024

Why this rating

Based on a meta-analysis of 45 articles, but limited by the lack of specific dermatological studies and reliance on case reports for side effects.

Source

A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists

Oluwafunke Oluwatosin Ogunremi et al. · International Journal of Women’s Dermatology · 2024

DOI 10.1097/jw9.0000000000000143

Meta-analysis · 45 studiesCited 6×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →